Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Jun 16;7(6):e571.
doi: 10.1038/bcj.2017.49.

Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit

M A Dimopoulos  1 , M Roussou  1 , M Gavriatopoulou  1 , D Fotiou  1 , D C Ziogas  1 , M Migkou  1 , I Panagiotidis  1 , E Eleutherakis-Papaiakovou  1 , N Kanellias  1 , E Psimenou  1 , S Marinaki  2 , D Bacharaki  3 , D Mparmparoussi  4 , C Matsouka  4 , S Giannouli  5 , E Terpos  1 , E Kastritis  1
Affiliations
Clinical Trial

Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit

M A Dimopoulos et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

EK: Genesis Pharma, Takeda, Janssen Amgen, Prothena; ET: BMS, Janssen, Celgene, Takeda Genesis Pharma, Amgen, Novartis and MAD: Novartis, Janssen, Celgene, Takeda, BMS, Amgen. The remaining authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(a) time to renal recovery and discontinuation of dialysis in 52 consecutive patients with newly diagnosed myeloma requiring dialysis for end stage renal disease, (b) survival of patients who discontinued dialysis at landmark analysis and (c) survival according to the presence of high-risk cytogenetics.
See this image and copyright information in PMC

References

    1. Dimopoulos MA, Delimpasi S, Katodritou E, Vassou A, Kyrtsonis MC, Repousis P et al. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol 2014; 25: 195–200. - PubMed
    1. Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E et al. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol 2016; 34: 1544–1557. - PubMed
    1. Fotiou D, Dimopoulos MA, Kastritis E. Managing renal complications in multiple myeloma. Expert Rev Hematol 2016; 9: 839–850. - PubMed
    1. Torra R, Blade J, Cases A, Lopez-Pedret J, Montserrat E, Rozman C et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 1995; 91: 854–859. - PubMed
    1. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000; 65: 175–181. - PubMed